1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

BridgeBio’s Attruby Off To A Strong Start – But Alnylam Awaits

 
• By Andrew McConaghie

Attruby is making fast inroads thanks to its edge over Pfizer’s established Vyndaqel, but will soon face competition from Alnylam.

BridgeBio
• Source: Shutterstock

BridgeBio’s Attruby has got off to a strong start in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, racking up better-than-expected sales in its first few months on the market.

Attruby (acoramidis) is mounting a challenge to Pfizer’s established treatment, Vyndaqel/Vyndamax (tafamidis), which until now has been the only approved...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Business

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.